← Back to Search

Aldose Reductase Inhibitor

Lidorestat for Diabetic Neuropathy

Phase 2
Waitlist Available
Research Sponsored by The Institute for Diabetes Discovery, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of Type 1 or Type II diabetes with mild to moderate diabetic peripheral neuropathy
Healthy status except for diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is to study an investigational drug -lidorestat- which is intended to stop or slow the progression of diabetic peripheral neuropathy.

Who is the study for?
This trial is for adults with Type 1 or Type 2 diabetes who have mild to moderate diabetic neuropathy. Participants must be in good health apart from diabetes, not pregnant or breastfeeding, and able to visit the clinic often over seven months. Those with uncontrolled high blood pressure or serious kidney/liver disease cannot join.Check my eligibility
What is being tested?
The study is testing Lidorestat (IDD-676) to see if it can halt or slow down the worsening of nerve damage caused by diabetes. The goal is to find a safe and effective dose through regular monitoring at the clinic.See study design
What are the potential side effects?
While specific side effects are not listed here, investigational drugs like Lidorestat may cause unexpected reactions due to their new nature. Common drug-related issues could include stomach upset, dizziness, allergic reactions, or other symptoms depending on individual tolerance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have Type 1 or Type 2 diabetes with mild to moderate nerve pain.
Select...
I am healthy except for having diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

The Institute for Diabetes Discovery, LLCLead Sponsor

Media Library

Lidorestat (IDD-676) (Aldose Reductase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00043797 — Phase 2
Diabetic Polyneuropathy Research Study Groups:
Diabetic Polyneuropathy Clinical Trial 2023: Lidorestat (IDD-676) Highlights & Side Effects. Trial Name: NCT00043797 — Phase 2
Lidorestat (IDD-676) (Aldose Reductase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00043797 — Phase 2
Diabetic Polyneuropathy Patient Testimony for trial: Trial Name: NCT00043797 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many health care facilities have initiated this experiment?

"There are 14 locations where patients can enroll in this trial, such as the University of Oklahoma in Oklahoma City, Glendale Adventist Medical Center in Glendale, and Diabetes & Endocrine Associates in La Jolla."

Answered by AI

Has the FDA sanctioned this particular treatment?

"This treatment's safety has been partially substantiated, thus receiving a rating of 2. Although data is present that attests to the remedy's security profile, there are yet no studies affirming its efficacy."

Answered by AI

Does this medical experiment include participants over the age of fifty-five?

"To be considered for this trial, applicants must range in age from 18 to 70 years old. Moreover, there are 4 studies geared towards younger people and 62 trials available specifically to those over 65."

Answered by AI

Who else is applying?

What state do they live in?
Virginia
Florida
California
How old are they?
18 - 65
65+
What site did they apply to?
Glendale Adventist Medical Center
Radiant Research
Other
Diabetes & Endocrine Associates
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
0

What questions have other patients asked about this trial?

How can i help?
PatientReceived 1 prior treatment

Why did patients apply to this trial?

I want to help cure or find a way to relief pain for myself or others that have neuropathy!
PatientReceived 2+ prior treatments
I suffer from neuropathy and I would like to be a part of finding a cure for others that have the same infliction.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy
2024. "Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00043797.
All > Neuropathy > Diabetic Neuropathy
~233 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top